The estimated Net Worth of Jane Lebkowski is at least $2.62 Million dollars as of 14 June 2011. Jane Lebkowski owns over 25,262 units of Geron stock worth over $2,494,196 and over the last 21 years Jane sold GERN stock worth over $121,420.
Jane has made over 2 trades of the Geron stock since 2011, according to the Form 4 filled with the SEC. Most recently Jane sold 25,262 units of GERN stock worth $108,121 on 14 June 2011.
The largest trade Jane's ever made was selling 25,262 units of Geron stock on 14 June 2011 worth over $108,121. On average, Jane trades about 1,345 units every 1 days since 2003. As of 14 June 2011 Jane still owns at least 568,154 units of Geron stock.
You can see the complete history of Jane Lebkowski stock trades at the bottom of the page.
Jane's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury und Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: